caa a22 4500 477058299 CHVBK 20180405111353.0 cr unu---uuuuu 170330e19960201xx s 000 0 eng 10.1007/BF00203773 doi (NATIONALLICENCE)springer-10.1007/BF00203773 Histamine-1 receptor blockade does not prevent nitroglycerin induced migraine [Elektronische Daten] Support for the NO-hypothesis of migraine [L. Lassen, L. Thomsen, C. Kruuse, H. Iversen, J. Olesen] It has previously been shown that in migraine sufferers infusion of glyceryl trinitrate (GTN) and histamine causes an immediate headache during the infusion and a genuine migraine attack one to several hours after the infusion. This identical time profile indicates a common mechanism of action. To evaluate whether GTN causes headache via liberation of histamine, we studied the effect of GTN 0.5 ώg · kg−1·min−1 for 20 min in seven migraine sufferers, once after pretreatment with the histamine-1(H1)-receptor blocker mepyramine (0.5 mg · kg−1) and once without pretreatment. This mepyramine dose is known to completely abolish histamine-induced headache. After pretreatment with mepyramine five patients experienced migraine, and without pretreatment six patients did so. The median peak headache score was 7 on a 0-10 scale with and without mepyramine pretreatment. The arterial responses, evaluated with transcranial Doppler, were also unaffected by the mepyramine pretreatment. Our results demonstrate that neither headache nor arterial dilatation due to GTN infusion is caused by histamine release. In all likelihood the common mediator of migraine induction by GTN and histamine is nitric oxide. Springer-Verlag, 1996 Migraine nationallicence Histamine nationallicence nitric oxide nationallicence glyceryl trinitrate nationallicence cerebral arteries nationallicence transcranial Doppler nationallicence Lassen L. Department of Neurology, Glostrup Hospital, University of Copenhagen, Ndr. Ringvej, DK-2600, Glostrup, Denmark aut Thomsen L. Department of Neurology, Glostrup Hospital, University of Copenhagen, Ndr. Ringvej, DK-2600, Glostrup, Denmark aut Kruuse C. Department of Neurology, Glostrup Hospital, University of Copenhagen, Ndr. Ringvej, DK-2600, Glostrup, Denmark aut Iversen H. Department of Neurology, Glostrup Hospital, University of Copenhagen, Ndr. Ringvej, DK-2600, Glostrup, Denmark aut Olesen J. Department of Neurology, Glostrup Hospital, University of Copenhagen, Ndr. Ringvej, DK-2600, Glostrup, Denmark aut European Journal of Clinical Pharmacology Springer-Verlag 49/5(1996-02-01), 335-339 0031-6970 49:5<335 1996 49 228 https://doi.org/10.1007/BF00203773 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00203773 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lassen L. Department of Neurology, Glostrup Hospital, University of Copenhagen, Ndr. Ringvej, DK-2600, Glostrup, Denmark aut NATIONALLICENCE 700 1- Thomsen L. Department of Neurology, Glostrup Hospital, University of Copenhagen, Ndr. Ringvej, DK-2600, Glostrup, Denmark aut NATIONALLICENCE 700 1- Kruuse C. Department of Neurology, Glostrup Hospital, University of Copenhagen, Ndr. Ringvej, DK-2600, Glostrup, Denmark aut NATIONALLICENCE 700 1- Iversen H. Department of Neurology, Glostrup Hospital, University of Copenhagen, Ndr. Ringvej, DK-2600, Glostrup, Denmark aut NATIONALLICENCE 700 1- Olesen J. Department of Neurology, Glostrup Hospital, University of Copenhagen, Ndr. Ringvej, DK-2600, Glostrup, Denmark aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 49/5(1996-02-01), 335-339 0031-6970 49:5<335 1996 49 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer